951656-07-8

Upstream product

• 3457-45-2 p-formylacetophenone 
• 80463-23-6 4-(1,3-dioxolan-2-yl)acetophenone 

Downstream Products

• 951656-09-0 4-(benzofuran-2-carbonyl)benzaldehyde 
• 118001-70-0 4-imidazo[1,2-a]pyrimidin-2-ylbenzaldehyde 
• 118001-68-6 4-imidazo[2,1-b]thiazol-6-yl-benzaldehyde 
• 1198171-03-7 ethyl 2-(4-(morpholinomethyl)phenyl)imidazo[1,2-a]pyridine-8-carboxylate 
• 1198171-05-9 2-(4-(morpholinomethyl)phenyl)imidazo[1,2-a]pyridine-8-carboxylic acid 
• 951656-15-8 trans-3-[4-(benzofuran-2-carbonyl)phenyl]-N-(tetrahydropyran-2-yloxy)acrylamide 
• 951656-13-6 trans-3-[4-(benzofuran-2-carbonyl)phenyl]acrylic acid 
• 951656-11-4 trans-3-[4-(benzofuran-2-carbonyl)phenyl]acrylic acid tert-butyl ester 
• 1198170-97-6 ethyl 2-(4-formylphenyl)imidazo[1,2-a]pyridine-8-carboxylate 

Relevant academic research and scientific papers

FUSED IMIDAZOLES FOR CANCER TREATMENT

Compounds of Formula (I), a tautomer or stereoisomer thereof, or a salt thereof,wherein ring B and the imidazole to which it is fused, R4, R6 and R7 have the meanings as given in the description and the claims, are effective inhibi tors of the Pi3K/Akt pathway.

IMIDAZOPYRIDINE AND RELATED ANALOGS AS SIRTUIN MODULATORS

Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

FUSED BICYCLIC IMIDAZOLES

Compounds of formula (I) a tautomer or stereoisomer thereof, or a salt thereof, wherein ring B and the imidazole to which it is fused, R4, R6 and R7 have the meanings as given in the description and the claims, are effective inhibitors of the Pi3K/Akt pathway.

2-Aroylindoles and 2-aroylbenzofurans with N-hydroxyacrylamide substructures as a novel series of rationally designed histone deacetylase inhibitors

Histone deacetylase (HDAC) inhibitors are considered to be drugs for targeted cancer therapy and second-generation HDIs are currently being tested in clinical trials. Here, we report on the synthesis and biological evaluation of a novel HDAC inhibitor sca